Table 1.
Chemotherapy-induced changes in circulating miRNAs concentrations.
Fig 1.
Study Design: Platinum resistant ovarian cancer subjects treated with decitabine and carboplatin.
Fourteen platinum resistant ovarian cancer patients were treated with decitabine/carboplatin in a phase II clinical trial. For the first chemotherapy cycle, decitabine was given daily for 5 days; followed by carboplatin given on day 8. miRNA analysis used plasma samples collected at baseline (prior to start of cycle one treatment) and at day 29 (prior to start of second cycle).
Fig 2.
Number of cycles of chemotherapy completed by each subject.
The patients’ are numbered and ordered based on the number of received cycles of chemotherapy. Patients were separated by a red line to distinguish chemotherapy responders and non-responders. Responders remained free of disease progression for at least 6 cycles (n = 6); and non-responders remained free of disease progression less than 6 cycles (n = 8). Each cycle was 28 days long.
Fig 3.
Circulating miRNAs visually differentiate patients into different groups.
Patients are numbered (left side of Fig 3) according to convention established, see Fig 2. Patients grouped visually based on clustering (red numbers = group 1, green numbers = group 2, and blue numbers = group 3). The clustering was based on similarity between the changes in miRNA concentrations between baseline (dCT baseline) and after chemotherapy treatment (dCT treatment). Blue = decreased concentrations after chemotherapy, Red = increased concentrations after treatment.
Fig 4.
Lower concentrations of miR-148-5p after decitabine/carboplatin chemotherapy compared to baseline predicts worse progression free survival.
For the Kaplan Meier progression free survival curve, patient samples were divided into 2 groups by the median value of the “–delta delta CT” values (post treatment value subtracted from baseline value). The log-rank test was between plasma miRNA concentration (high [red line] vs. low [black line]) with the time to non-response, and p value less than 0.05 was considered significant. The inset plots the raw CT values of all patient samples for miR-148-5p, dashed lines—non-responders, solid lines—responders.